Hybio Pharmaceutical Co., Ltd.
300199
Classement en actions
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Prix de l'action
$3.69
Capitalisation boursière
$3.11B
Changement (1 jour)
-7.75%
Changement (1 an)
21.56%
Pays
CN
Échange Hybio Pharmaceutical Co., Ltd. (300199)
Catégorie
Healthcare
Historique du prix de l'action pour Hybio Pharmaceutical Co., Ltd. (300199)
Prix de clôture le plus élevé : $3.66 le 2026-10-01
Prix de clôture le plus bas : $0.58 le 2011-04-01
Prix de clôture le plus bas : $0.58 le 2011-04-01
Historique du prix de l'action de Hybio Pharmaceutical Co., Ltd. de 2011 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 16.04% |
| 2025 | 42.29% |
| 2024 | -6.38% |
| 2023 | -30.94% |
| 2022 | 109.62% |
| 2021 | 23.92% |
| 2020 | 37.43% |
| 2019 | -46.61% |
| 2018 | -38.55% |
| 2017 | -7.67% |
| 2016 | -34.21% |
| 2015 | 61.85% |
| 2014 | 66.85% |
| 2013 | 185.59% |
| 2012 | -33.66% |
| 2011 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $165.31 | 23.62% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $224.81 | 31.28% |
CH
|
|
| $18.43 | -4.03% |
IN
|
